XNYS · Drug Manufacturers - General
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$1,152.93+0.04%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
62/100
Positive
Score components
TickerWhale View
Lilly(Eli) & Company scores 62 out of 100 overall, which we rate positive. Quality & growth is its strongest area and Valuation its weakest.
What helps
- Technical
- Quality & growth
- Sentiment Signal
What to watch
- Valuation
- Risk
Quality & growth
30%99Strong
- Revenue growth 49.6%
- EPS growth 94.8%
Valuation
25%8Weak
- P/E 38.6
- EV/Sales 13.5
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
#11 by market cap in our coverage · ~50,000 employees · Listed 1970-07-09 · www.lilly.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#41 / 139sector rank by TickerWhale Score
TickerWhale Score 62 vs sector average 55.1 (+6.9)
Revenue growth (industry)Top 9%
Gross margin (industry)Top 9%
Return on equity (industry)Top 20%
P/E (industry)Pricier than 70%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
79/100Strong vs universe
Ranks 79th of 100 covered names on our technical composite — the composite itself scores 63/100 · 25% of the TickerWhale Score
Classic chart indicators
Sell
1 buy · 2 sell · 5 neutral of 8 votes
TickerWhale rates LLY's technical setup strong — 79th percentile of the covered universe. Classic chart indicators lean sell — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
4 / 9constructive
- vs 200-day+8.1%
- vs 50-day-2.1%
Momentum
Mixed
- RSI (14)47 · neutral
- Stochasticbuy
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength8· weak trend
- MACD (12,26,9)sell(histogram -0.202)
How the classic verdict is reached
Moving averages (9) agree on neutral — 4 buy vs 4 sell — and carry one vote between them.
Oscillators (7) vote individually: 1 buy · 2 sell · 4 neutral.
Result — 1 buy vs 2 sell of 8 votes = Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)38.6
- P/S (TTM)12.9
- P/B30.4
- EV/EBITDA—
- EV/Sales13.5
- PEG—
Profitability & returns
- Gross margin83.4%
- Net margin33.5%
- ROE82.1%
- Debt/Equity1.62
Growth
- Revenue growth (YoY)49.6%
- EPS growth (YoY)94.8%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $1.03T
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $65.2B | $45.0B | $34.1B |
| Gross profit | $54.1B | $36.6B | $27.0B |
| Operating income | $26.3B | $12.9B | $6.5B |
| Net income | $20.6B | $10.6B | $5.2B |
| EPS (diluted) | $22.95 | $11.71 | $5.80 |
| Free cash flow | $9.0B | $3.8B | $792M |
| Cash | $7.3B | $3.3B | $2.8B |
| Total debt | $42.5B | $33.6B | $25.2B |
| Equity | $26.5B | $14.3B | $10.8B |
| Net debt | $35.2B | $30.4B | $22.4B |
| Debt / equity | 1.60 | 2.36 | 2.34 |
| Liabilities / assets | 0.76 | 0.82 | 0.83 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: MU →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLYCurrentLilly(Eli) & Company | 62 | 63 | 38.6 | — | 30.4 | 13.5 | $1,152.93 | +0.04% | +49.6% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.